SABS
SAB Biotherapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
SAB Biotherapeutics has 4 disclosed suppliers and 1 disclosed customer in SEC filings.
—
SAB Biotherapeutics, Inc.
3.34
SentenceThe Emergent Agreements contemplate that we will enter into one or more binding Master Manufacturing Services Agreements, whereby Emergent will provide contract development and manufacturing services to produce our fully-human polyclonal antibody products.
SentenceFor SAB-142, Avance Clinical PTY, Ltd ("Avance"), acts as the contract research organization ("CRO") overseeing our Phase 1 safety study.
SABS 10-Kaccession 0001833214-26-000003
SentenceFortrea will act as the CRO overseeing our Phase 2b efficacy and safety study for SAB-142.
SABS 10-Kaccession 0001833214-26-000003
SentenceWe acquired all the intellectual property rights to Tc Bovine and the production platform from Sanford Applied Biosciences, a wholly owned subsidiary of Sanford Health, to develop targeted hIgG to specific targets and advance clinical development and commercialization.
SABS 10-Kaccession 0001833214-26-000003
SentenceWe had various grants from the US Department of Defense that terminated in 2022.
SABS 10-Kaccession 0001833214-26-000003
Linked news
Expected move
No implied move.